The stock of Revolution Medicines Inc (RVMD) has gone up by 0.88% for the week, with a 19.00% rise in the past month and a 37.29% rise in the past quarter. The volatility ratio for the week is 6.17%, and the volatility levels for the past 30 days are 5.12% for RVMD.. The simple moving average for the past 20 days is 13.01% for RVMD’s stock, with a 31.05% simple moving average for the past 200 days.
Is It Worth Investing in Revolution Medicines Inc (NASDAQ: RVMD) Right Now?
Moreover, the 36-month beta value for RVMD is 1.47. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RVMD is 136.49M and currently, short sellers hold a 8.79% of that float. On April 18, 2024, RVMD’s average trading volume was 1.44M shares.
RVMD) stock’s latest price update
Revolution Medicines Inc (NASDAQ: RVMD)’s stock price has gone rise by 1.57 in comparison to its previous close of 36.25, however, the company has experienced a 0.88% increase in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-04 that REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum.
Analysts’ Opinion of RVMD
Many brokerage firms have already submitted their reports for RVMD stocks, with Needham repeating the rating for RVMD by listing it as a “Buy.” The predicted price for RVMD in the upcoming period, according to Needham is $46 based on the research report published on April 12, 2024 of the current year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see RVMD reach a price target of $48, previously predicting the price at $36. The rating they have provided for RVMD stocks is “Strong Buy” according to the report published on April 10th, 2024.
Piper Sandler gave a rating of “Overweight” to RVMD, setting the target price at $43 in the report published on March 11th of the current year.
RVMD Trading at 17.52% from the 50-Day Moving Average
After a stumble in the market that brought RVMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.93% of loss for the given period.
Volatility was left at 5.12%, however, over the last 30 days, the volatility rate increased by 6.17%, as shares surge +19.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.37% upper at present.
During the last 5 trading sessions, RVMD rose by +0.88%, which changed the moving average for the period of 200-days by +37.64% in comparison to the 20-day moving average, which settled at $32.88. In addition, Revolution Medicines Inc saw 28.38% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RVMD starting from GOLDSMITH MARK A, who sale 10,000 shares at the price of $35.33 back on Apr 10 ’24. After this action, GOLDSMITH MARK A now owns 30,424 shares of Revolution Medicines Inc, valued at $353,346 using the latest closing price.
GOLDSMITH MARK A, the of Revolution Medicines Inc, sale 7,500 shares at $35.48 during a trade that took place back on Apr 10 ’24, which means that GOLDSMITH MARK A is holding 452,879 shares at $266,122 based on the most recent closing price.
Stock Fundamentals for RVMD
Current profitability levels for the company are sitting at:
- -42.07 for the present operating margin
- 0.2 for the gross margin
The net margin for Revolution Medicines Inc stands at -36.85. The total capital return value is set at -0.25. Equity return is now at value -34.75, with -29.82 for asset returns.
Based on Revolution Medicines Inc (RVMD), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -3.99. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is 1607.87.
Currently, EBITDA for the company is -477.88 million with net debt to EBITDA at 1.26. When we switch over and look at the enterprise to sales, we see a ratio of 471.13. The receivables turnover for the company is 9.23for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.06.
Conclusion
To wrap up, the performance of Revolution Medicines Inc (RVMD) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
